I

Injective

INJ

RootData List 2023

Layer 1 blockchain built

Performances

Comparison:
1h24h7d30d60d90d
1.03%1.94%42.86%34.35%51.91%83.13%

Comparison

Total Raised:--

Fundraising not disclosed

FDV:--

Token not listed

24h Trading Volume:--

Token not listed

Details

This content is generated by RD AI and is for reference only

Injective is a Layer 1 blockchain purpose-built for financial applications, featuring an order book module and cross-chain interoperability. It supports decentralized exchanges, derivatives, tokenization of real-world assets, and stablecoin payments, allowing developers to deploy applications rapidly via pluggable modules. Usage involves creating a wallet, acquiring INJ tokens, bridging assets, and deploying smart contracts, with native EVM compatibility to lower migration costs. It achieves fast block confirmation and low transaction fees, while enhancing market efficiency through shared liquidity pools.

Ecosystem(1):
Founded:
2018

Event Calendar

Jul 29, 2020
Injective raised $ 2.6 M in Seed round
Oct 20, 2020
Injective raised $ 3.6 M in Public Sale round
Oct 31, 2020
INJ is live for trading
Apr 21, 2021
Injective raised $ 10 M in OTC round
Aug 10, 2022
Injective raised $ 40 M in OTC round
Oct 17, 2024

Open Markets

#ExchangePairPrice+2% depth-2% depthVolume (24h)volume %

Related News

Follow Updates

Follow Lists

People

About Injective

Founded in 2018 by Eric Chen and Albert Chon, Injective is a layer-1 blockchain optimized for financial applications, incubated by Binance Labs. Key milestones include: a $10 million funding round in 2021 with backing from Jump Crypto, Pantera Capital, and Mark Cuban; a governance proposal that activated a deflationary mechanism with 99.89% support, drastically reducing token supply; support for native USDC and integration of Circle's cross-chain transfer protocol, strengthening stablecoin infrastructure; the launch of the RWA tokenization platform Injective Mint and submission of a transfer agent registration application to the SEC, advancing compliant on-chain securities infrastructure; Bitnomial's listing of INJ futures in the US, paving the way for spot ETFs; and POSCO International and LG CNS tokenizing real trade receivables on Injective, expanding real-world asset applications.

Updated: Aug 29, 2026

Positive:

On Aug 19, Injective's affiliate obtained SEC transfer agent qualification, becoming the first Layer 1 with this status to record tokenized security ownership; INJ rose 12.67% in a day.

On Sep 8, staked INJ hit an all-time high above 58.8 million; the September community buyback burned 25,200 INJ, tightening supply.

RWA perpetual trading volume surpassed $5.3 billion; August monthly volume reached $209.7 million; CFTC approved regulated INJ futures on Bitnomial.

Negative:

On Aug 31, Injective halted block production for ~4 hours due to an exploit of core modules; ~$4.9M was bridged to Ethereum; exchanges temporarily restricted INJ transfers.

Updated: Sep 14, 2026

Injective's co-founders and core executives include:

Eric Chen (Co-founder & CEO) - Chinese-American entrepreneur and blockchain developer. Born August 28, 1998 in Shenzhen, China. Studied finance and computer science at NYU. Previously worked as a researcher at Innovating Capital (2017-2018). Co-founded Injective Labs in 2018. Announced inSVM rollup in March 2023 and integrated Pyth oracle in May 2023. Named in Forbes 30 Under 30 Finance in 2024.

Albert Chon (Co-founder & CTO) - Previously a Software Development Engineer at Amazon, Consultant at OpenZeppelin, and Full Stack Software Engineer at Linc Global. Holds an MS in Computer Science from Stanford University (specialization in Systems), advised by Dan Boneh and Mendel Rosenblum. Also served as a researcher at Stanford's Parallel Distributed Processing Lab.

Bojan Angjelkoski (Engineering Director) - Previously a Full Stack Engineer at the World Trade Organization. Graduated from the University of Belgrade.

Noah Axler (General Counsel) - Previously Chief Legal Officer at Terraform Labs. Graduated from University of Pennsylvania Carey Law School and University of Pittsburgh.

Mirza Uddin (Core Contributor) - Currently Head of Business Development at Injective. Also Co-founder & General Partner at Vessel Capital (a $55M operator-led fund). Previously interned at Two Sigma and Index Ventures. Graduated from Harvard University with a Bachelor's in Government.

Updated: Aug 29, 2026